Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-180-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- other: Expert Statement
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- other: Expert Statement
- Title:
- Unnamed
- Year:
- 2 006
- Report date:
- 2006
Materials and methods
- Principles of method if other than guideline:
- Expert statement
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
- Type:
- Constituent
Administration / exposure
- Duration and frequency of treatment / exposure:
- Expert statement. No animal study.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
Expert statement. No animal study.
- No. of animals per sex per dose / concentration:
- Expert statement. No animal study.
Results and discussion
- Preliminary studies:
- NA
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- MDA is determined by the compounds hydrolysis products Diisopropylamide (DPA) and magnesium hydroxide and magnesium oxide, respectively.
Diisopropylamide (DPA) / adsorption:
DPA was shown to be corrosive in eye irritation and skin irritation studies.
DPA is a liquid with a molecular weight of 101.19 g/mol. Its chemical structure reveals high polarity. Correspondingly its water solubility is relatively high (110 g/L). Its partition coefficient was determined to be logPow = 1.40 and its vapour pressure 79.4 mm Hg.
DPA is rather unlikely to penetrate skin to any significant extent, as although the molecule is rather small and its logPow is > 1, (but also < 2 and thus not optimal for dermal absorption), it is highly polar and highly hydrophilic. Further, with a vapour pressure of 79.4 mm Hg, DPA will evaporate to some extent.
Magnesium oxide (MgO):
MgO is a crystalline mineral of low molecular weight (MW = 40.30 g/mol). Its water solubility is very low (< 1 mg/L). Intake is most likely to occur orally. Naturally, magnesium compounds are taken up in food and drinking water. MgO does not absorb across the skin, however local irritation and corrosion may be caused due to the compounds alkalinity.
Following oral ingestion of magnesium compounds, such as MgO or Mg(OH)2, the sub-stances generally dissociate in the stomach (acid conditions). The available Mg2+ ion is then absorbed along the entire intestinal tract, with the distal jejunum and ileum as sites of maximal magnesium absorption. The net absorption of magnesium is approximately 50 %, depending on dietary constituents. - Details on distribution in tissues:
- Diisopropylamide (DPA) / distribution:
If absorbed by skin, systemic DPA toxicity is low, as shown in the acute dermal toxicity study, where no effects were observed. However, local application DPA can cause corrosion to skin and eyes, as the substance is rather alkaline.
Administered orally, DPA is likely to dissolve in the stomach, due to its high water solubility, and may be absorbed via the gastro-intestinal tract. In any case, toxicity to orally administered DPA is low, as shown in acute and subacute toxicity tests.
Magnesium oxide (MgO):
Determined by atomic spectroscopy the total body burden in an average adult is 25 g. Ra-dioactive studies revealed that magnesium is incorporated in all organs; approximately 60 % of that amount is present in bone, 20 % is localised in muscle and the remaining 20 % is present in soft tissue and liver.
- Details on excretion:
- Diisopropylamide (DPA) / excretion:
See details on metabolites.
Magnesium oxide (MgO):
See details on metabolites.
Metabolite characterisation studies
- Details on metabolites:
- Diisopropylamide (DPA) / metabolism:
Absorbed by the body, following ingestion or passage through the skin, DPA is likely to be metabolised and the parent compound and degradation products distributed via systemic circulation. During metabolism the hydrophilic DPA may be rendered even more polar. For example, the flavin monooxygenase system could produce the hydroxylamine through N-hydroxylation, catalysed by the flavin monooxygenase system. Several phase I metabolic reactions, including several reduction and hydrolysis reactions, catalysed by cytochrome P-450-dependent monooxygenase enzymes may also occur, including metabolic conversion of the amide group by e.g. N-dealkylation and/or N-hydroxylation. Parent compound and me-tabolites formed in phase I metabolic reactions may be rendered more polar by phase II me-tabolism in subsequent steps. Finally, remaining amounts of the parent compound and formed metabolites are expected to be excreted in urine or bile.
It is unlikely that DPA is metabolised to more reactive (toxic) products. This assumption is supported by results obtained in oral and dermal toxicity studies and two in vitro tests. In both the in vivo studies toxicity was low. In an Ames test and a chromosome aberration assay no significant increase in toxicity was noted in the presence of a rodent microsomal S9-fraction, when compared to incubation without S9-fraction. Together, this data indicates that formation of reactive metabolites is rather unlikely.
Local tissue damage is the main toxicity caused by DPA, due to its irritative nature. Based on the compound’s structure and associated physical-chemical characteristics, bioaccumulation is not likely to occur. Becoming bioavailable, the substance or its metabolites are expected to be well distributed throughout the body fluids and rapidly excreted via urine (non-conjugated forms) or via faces (high molecular weight conjugated forms). Formation of toxic metabolites is unlikely.
Magnesium oxide (MgO):
It has been estimated that 99 % of the total body magnesium is present intracellularly. Of the extracellular fluid magnesium, 75 to 80 % is unfilterable and 20 % is protein bound.
Magnesium is an important element in vitamin D metabolism and/or action. The secretion of parathyroid hormone is stimulated by low concentrations of magnesium. Further, magnesium may cause hypocalcemia. A wide variety of hormones have been implicated in magnesium homeostasis by affecting urinary magnesium excretion, including calcitonin, thyroxine, gluco-corticoids, glucagon and angiotensins.
The kidney is the principal organ involved in magnesium homeostasis. Approximately 80 % of plasma magnesium is unbound and available for glomular filtration by the Kidney. Under normal conditions, 95 % of the filtered load of magnesium is reabsorbed by the kidney and 5 % is excreted in urine. Considerable reabsorption of filtered magnesium is known to occur in the proximal tubules of the kidney.
Applicant's summary and conclusion
- Executive summary:
The hydrolysis of MDA in contact with water is spontaneous and takes place instantaneously. In the course of the authorisation according to 67/548/EEC and 92/32/EEC (ID 06-04-2090-00) it was agreed with the German competent authority (BAuA) that no toxicological testing of MDA was carried out. Thus, the toxicokinetic profile of MDA is determined by the compounds hydrolysis products Diisopropylamide (DPA) and magnesium hydroxide and magnesium oxide, respectively. Both, DPA and magnesium are of relatively low acute toxicity. Local irritation may occur, due to the alkaline properties inherent to both compounds. Systemic toxicity is most likely due to secondary effects. Subacute oral administration revealed NOAEL values of 15 mg/kg bw/day and > 1000 mg/kg bw/day for DPA and Mg(OH)2, respectively. Both hydrolysis products were negative in several in vitro genotoxicity test systems, without and with metabolic activation. For DPA bioaccumulation is not likely to occur, based on structure and associated physical-chemical characteristics. Becoming bioavailable, the substance or its metabolites are expected to be well distributed throughout the body fluids and rapidly excreted via urine (non-conjugated forms) or via faces (high molecular weight conjugated forms). Formation of toxic DPA metabolites is unlikely. Magnesium is an essential element, involved in several cellular and hormonal pathways. Absorbed by the body Mg2+ ions stored in the body and resorbed by the kidney. Only excess amounts are eventually excreted in the urine. The total body burden in an average adult (70 kg) is 25 g, equivalent to 357 mg/kg bw.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.